Abstract

This study investigates the efficacy of sertraline combined with agomelatine in the treatment of mild to moderate depression and its impact on cognitive function. A retrospective analysis was made considering 90 individuals with mild to moderate depression. According to the actual medication, they were divided into research group and control group, with 45 individuals in each group. Both the groups were given sertraline, and the research group was given a combination of agomelatine along with sertraline for 6 w. The clinical effects, positive and negative symptom scores, depression scores, sleep quality index scores, cognitive function scores and adverse drug events were compared between the two groups. After medication, the clinical effect of the research group was better than that of the control group (p<0.05). The depression score, positive and negative symptom scores, and sleep quality index scores of the research group were lower than those of the control group (p<0.05). The cognitive function score of the research group was higher compared with the control group (p<0.05). There was no significant difference in adverse drug events between the two groups (p>0.05). Compared with the use of sertraline alone, sertraline combined with agomelatine has better clinical effects in the treatment of mild to moderate depression, helping to relieve individuals' depressive symptoms, sleep quality, cognitive function, and drug safety is high.